Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers - A double-blind, placebo-controlled PET study with [F-18]FDG
Autore:
Gouzoulis-Mayfrank, E; Schreckenberger, M; Sabri, O; Arning, C; Thelen, B; Spitzer, M; Kovar, KA; Hermle, L; Bull, U; Sass, H;
Indirizzi:
Univ Technol RWTH, Dept Psychiat & Psychotherapy, D-52074 Aachen, Germany Univ Technol RWTH Aachen Germany D-52074 herapy, D-52074 Aachen, Germany Univ Technol RWTH, Dept Nucl Med, D-52074 Aachen, Germany Univ Technol RWTH Aachen Germany D-52074 cl Med, D-52074 Aachen, Germany Univ Ulm, Dept Psychiat, Ulm, Germany Univ Ulm Ulm GermanyUniv Ulm, Dept Psychiat, Ulm, Germany Univ Tubingen, Inst Pharmaceut, Tubingen, Germany Univ Tubingen TubingenGermany ngen, Inst Pharmaceut, Tubingen, Germany Psychiat & Neurol Hosp Christophsbad, Goppingen, Germany Psychiat & NeurolHosp Christophsbad Goppingen Germany ppingen, Germany
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 6, volume: 20, anno: 1999,
pagine: 565 - 581
SICI:
0893-133X(199906)20:6<565:NEOP3(>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; BRAIN GLUCOSE-METABOLISM; DISORDERED SCHIZOPHRENIC-PATIENTS; NEUROLEPTIC-NAIVE PATIENTS; ANTERIOR CINGULATE CORTEX; F-18 FLUORODEOXYGLUCOSE; COMPUTED-TOMOGRAPHY; ACTIVATION; DYSFUNCTION;
Keywords:
psilocybin; MDE; ecstasy; methamphetamine; model psychosis; FDG-PET; activation study;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
88
Recensione:
Indirizzi per estratti:
Indirizzo: Gouzoulis-Mayfrank, E Univchen,nol RWTH, Dept Psychiat & Psychotherapy, Pauwellstr 30, D-52074 Aa Univ Technol RWTH Pauwellstr 30 Aachen Germany D-52074
Citazione:
E. Gouzoulis-Mayfrank et al., "Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers - A double-blind, placebo-controlled PET study with [F-18]FDG", NEUROPSYCH, 20(6), 1999, pp. 565-581

Abstract

The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4-methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2-0.4 mg/kg) and the drugs' interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each group: n = 8). Subjects underwent two scans (control:word repetition; activation: word association) within 2-4 weeks. Psilocybin increased rMRGlu in distinct right hemispheric frontotemporal cortical regions, particularly in the anterior cingulate and decreased rMRGlu in the thalamus. Both MDE and METH induced cortical hypometabolism and cerebellar hypermetabolism. In the MDE group, cortical hypometabolism was more pronounced in frontal regions, with the exception of the right anterior cingulate, which tended to be hyperactive. Cognitive activation-related increases in left frontocortical regions were attenuated under all three psychoactive substances, but less so under MDE. Taking into account performance data and subjective reports on task difficulty, these effects may result from different mechanisms across the three groups. Our PSI data are in line with studieson acute schizophrenic patients suggesting frontal overactivity at rest, bmt diminished capacity to activate prefrontal regions upon cognitive demand. The MDE data support the hypothesis that entactogens constitute a distinct psychoactive substance class, which takes an intermediate position between stimulants and hallucinogens. (C) 1999 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:34:14